IBDEI1F9 ; ; 19-NOV-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,23736,2)
 ;;=^5063612
 ;;^UTILITY(U,$J,358.3,23737,0)
 ;;=Z91.128^^113^1147^39
 ;;^UTILITY(U,$J,358.3,23737,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,23737,1,3,0)
 ;;=3^Pt's intent underdose of meds d/t oth reasons
 ;;^UTILITY(U,$J,358.3,23737,1,4,0)
 ;;=4^Z91.128
 ;;^UTILITY(U,$J,358.3,23737,2)
 ;;=^5063613
 ;;^UTILITY(U,$J,358.3,23738,0)
 ;;=Z63.71^^113^1147^44
 ;;^UTILITY(U,$J,358.3,23738,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,23738,1,3,0)
 ;;=3^Stress on family d/t rtrn of family member from deployment
 ;;^UTILITY(U,$J,358.3,23738,1,4,0)
 ;;=4^Z63.71
 ;;^UTILITY(U,$J,358.3,23738,2)
 ;;=^5063171
 ;;^UTILITY(U,$J,358.3,23739,0)
 ;;=Z03.89^^113^1148^1
 ;;^UTILITY(U,$J,358.3,23739,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,23739,1,3,0)
 ;;=3^Observation for Suspected Diseases & Condition Ruled Out
 ;;^UTILITY(U,$J,358.3,23739,1,4,0)
 ;;=4^Z03.89
 ;;^UTILITY(U,$J,358.3,23739,2)
 ;;=^5062656
 ;;^UTILITY(U,$J,358.3,23740,0)
 ;;=E11.9^^113^1149^11
 ;;^UTILITY(U,$J,358.3,23740,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,23740,1,3,0)
 ;;=3^Type 2 DM w/o Complications
 ;;^UTILITY(U,$J,358.3,23740,1,4,0)
 ;;=4^E11.9
 ;;^UTILITY(U,$J,358.3,23740,2)
 ;;=^5002666
 ;;^UTILITY(U,$J,358.3,23741,0)
 ;;=E11.65^^113^1149^9
 ;;^UTILITY(U,$J,358.3,23741,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,23741,1,3,0)
 ;;=3^Type 2 DM w/ Hyperglycemia
 ;;^UTILITY(U,$J,358.3,23741,1,4,0)
 ;;=4^E11.65
 ;;^UTILITY(U,$J,358.3,23741,2)
 ;;=^5002663
 ;;^UTILITY(U,$J,358.3,23742,0)
 ;;=E10.9^^113^1149^6
 ;;^UTILITY(U,$J,358.3,23742,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,23742,1,3,0)
 ;;=3^Type 1 DM w/o Complications
 ;;^UTILITY(U,$J,358.3,23742,1,4,0)
 ;;=4^E10.9
 ;;^UTILITY(U,$J,358.3,23742,2)
 ;;=^5002626
 ;;^UTILITY(U,$J,358.3,23743,0)
 ;;=E10.65^^113^1149^4
 ;;^UTILITY(U,$J,358.3,23743,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,23743,1,3,0)
 ;;=3^Type 1 DM w/ Hyperglycemia
 ;;^UTILITY(U,$J,358.3,23743,1,4,0)
 ;;=4^E10.65
 ;;^UTILITY(U,$J,358.3,23743,2)
 ;;=^5002623
 ;;^UTILITY(U,$J,358.3,23744,0)
 ;;=E11.42^^113^1149^7
 ;;^UTILITY(U,$J,358.3,23744,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,23744,1,3,0)
 ;;=3^Type 2 DM w/ Diabetic Polyneuropathy
 ;;^UTILITY(U,$J,358.3,23744,1,4,0)
 ;;=4^E11.42
 ;;^UTILITY(U,$J,358.3,23744,2)
 ;;=^5002646
 ;;^UTILITY(U,$J,358.3,23745,0)
 ;;=E10.42^^113^1149^2
 ;;^UTILITY(U,$J,358.3,23745,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,23745,1,3,0)
 ;;=3^Type 1 DM w/ Diabetic Polyneuropathy
 ;;^UTILITY(U,$J,358.3,23745,1,4,0)
 ;;=4^E10.42
 ;;^UTILITY(U,$J,358.3,23745,2)
 ;;=^5002606
 ;;^UTILITY(U,$J,358.3,23746,0)
 ;;=E13.42^^113^1149^1
 ;;^UTILITY(U,$J,358.3,23746,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,23746,1,3,0)
 ;;=3^Secondary Type DM w/ Diabetic Polyneuropathy
 ;;^UTILITY(U,$J,358.3,23746,1,4,0)
 ;;=4^E13.42
 ;;^UTILITY(U,$J,358.3,23746,2)
 ;;=^5002686
 ;;^UTILITY(U,$J,358.3,23747,0)
 ;;=E10.621^^113^1149^3
 ;;^UTILITY(U,$J,358.3,23747,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,23747,1,3,0)
 ;;=3^Type 1 DM w/ Foot Ulcer
 ;;^UTILITY(U,$J,358.3,23747,1,4,0)
 ;;=4^E10.621
 ;;^UTILITY(U,$J,358.3,23747,2)
 ;;=^5002616
 ;;^UTILITY(U,$J,358.3,23748,0)
 ;;=E10.649^^113^1149^5
 ;;^UTILITY(U,$J,358.3,23748,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,23748,1,3,0)
 ;;=3^Type 1 DM w/ Hypoglycemia w/o Coma
 ;;^UTILITY(U,$J,358.3,23748,1,4,0)
 ;;=4^E10.649
 ;;^UTILITY(U,$J,358.3,23748,2)
 ;;=^5002622
 ;;^UTILITY(U,$J,358.3,23749,0)
 ;;=E11.621^^113^1149^8
 ;;^UTILITY(U,$J,358.3,23749,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,23749,1,3,0)
 ;;=3^Type 2 DM w/ Foot Ulcer
